ECTRIMS: Roche's Ocrevus combats biomarker that may spur MS progression

10th September 2019 Uncategorised 0

Roche, already fast in grabbing multiple sclerosis market share with Ocrevus, has new data showing the drug’s impact on a biomarker may help predict disease progression. Patients with relapsing-remitting or primary progressive forms of MS saw their blood neurofilament light chain levels lowered to a healthy donor range after Ocrevus treatment, Roche said.

More: ECTRIMS: Roche's Ocrevus combats biomarker that may spur MS progression
Source: fierce